Moreover, a small-molecule DYRK1B-directed therapy combined with mTOR inhibition and conventional chemotherapy restricted the growth of established tumors and extended survival in an aggressive murine PDAC mouse model, significantly extending the understanding of DYRK1B as an anti-cancer target. This evidence concerns the gene DYRK1B and cancer.